Sun Pharma Recalls Dandruff, Acne Drugs, Cipla Pulls Lanreotide In US

The company initiated the Class III nationwide (US) recall on December 30, 2025.

The US Food and Drug Administration (USFDA) noted that the company is also recalling certain batches of a medication to treat acne vulgaris.

Sun Pharmaceutical Industries Inc initiated the Class III recall of Clindamycin Phosphate USP on November 26, 2025 due to "Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay", it added.

As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences".

In a seperate disclosure, USFDA stated that a US-based arm of Mumbai-headquartered drug maker Cipla is recalling 15,221 syringes in the US market.

The Warren (New Jersey)-based Cipla USA, Inc is recalling the Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringes due to the "presence of particulate matter", the USFDA noted.

The company initiated the Class II nationwide recall on January 2 this year.

As per the USFDA, a Class II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.

The US is the world's largest market for pharmaceutical products.